Avadel Pharmaceuticals (AVDL) Cash & Current Investments (2016 - 2022)
Historic Cash & Current Investments for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $106.5 million.
- Avadel Pharmaceuticals' Cash & Current Investments fell 4120.42% to $106.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $106.5 million, marking a year-over-year decrease of 4120.42%. This contributed to the annual value of $157.2 million for FY2021, which is 2898.84% down from last year.
- According to the latest figures from Q3 2022, Avadel Pharmaceuticals' Cash & Current Investments is $106.5 million, which was down 4120.42% from $104.1 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Cash & Current Investments registered a high of $238.6 million during Q2 2020, and its lowest value of $64.2 million during Q4 2019.
- Moreover, its 5-year median value for Cash & Current Investments was $125.3 million (2018), whereas its average is $144.8 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first crashed by 5970.78% in 2019, then surged by 24508.87% in 2020.
- Avadel Pharmaceuticals' Cash & Current Investments (Quarter) stood at $99.9 million in 2018, then crashed by 35.79% to $64.2 million in 2019, then surged by 245.09% to $221.4 million in 2020, then dropped by 28.99% to $157.2 million in 2021, then crashed by 32.28% to $106.5 million in 2022.
- Its Cash & Current Investments was $106.5 million in Q3 2022, compared to $104.1 million in Q2 2022 and $123.5 million in Q1 2022.